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ABSTRACT
Hepatocellular Carcinoma (HCC) commonly develops in chronically damaged liver 
tissues. The resulting regenerative and inflammatory processes create an adverse 
milieu that promotes tumor-initiation and progression. A better understanding of 
the hepatic tumor-microenvironment interaction might infer profound therapeutic 
implications. 
Integrative whole genome and transcriptome analyses of different tumor regions, 
the invasive tumor border and tumor-surrounding liver (SL) were performed to identify 
associated molecular alterations and integrated with our existing HCC database. 
Expression levels and localization of established CSC markers were assessed in pre-
neoplastic lesions and confirmed in two independent patient cohorts using qRT-PCR, 
immunohistochemistry and immunofluorescence. 
Our results indicate that genomic and transcriptomic profiles between SL and 
different tumor regions are quite distinct. Progressive increase in genetic alterations 
and activation of pathways related to proliferation as well as apoptosis were observed 
in the tumor tissue, while activation of stemness markers was present in cirrhotic 
SL and continuously decreased from pre-neoplastic lesions to HCC. Interestingly, 
the invasive tumor border was characterized by inflammatory and EMT-related gene 
sets as well as activation of pro-survival signaling. Consistently, integration of gene 
expression signatures with two independent HCC databases containing 300 HCCs 
revealed that border signatures are predictive of HCC patient survival. 
Prognostic significance of the permissive liver microenvironment might be a 
consequence of a pro-oncogenic field effect that is caused by chronic regenerative 
processes. Activation of key oncogenic features and immune-response signaling 
indicates that the cross-talk between tumor and microenvironment might be a 
promising therapeutic and/or preventive target.
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INTRODUCTION
Hepatocellular carcinoma (HCC) ranks among the 
most common cancers worldwide [1]. In the vast majority 
of patients HCC develops on the basis of an underlying 
chronic liver disease, whereby the chronic liver damage 
induces subsequent regenerative and inflammatory 
processes [2]. A constant remodeling of the diseased liver 
parenchyma and activation of immune-cell mediated 
inflammation creates an adverse milieu that promotes HCC 
development [3]. As a result, a significant phenotypic and 
molecular heterogeneity is observed in HCC that hampers 
therapeutic progress and, to date, sorafenib remains the 
only approved therapy for advanced HCC [4]. 
It is well recognized that acquisition of pre-
neoplastic (epi-)genetic alterations in the hepatic 
microenvironment induces a continuum of morphologic 
changes from chronic inflammatory cell death over 
cirrhosis to dysplastic lesions which promotes malignant 
transformation [5]. Intense cross-talk between cancer 
cells and stromal/immune cells further promotes HCC 
development and progression in the majority of HCCs 
[6]. Also, activation of pro-inflammatory cytokines (e.g. 
acquisition of autocrine IL6 signaling in hepatic progenitor 
cells) induces a broad range of effects on a variety of 
resident and non-resident cells (e.g. immune cells) and can 
be considered a key oncogenic driver in HCC development 
[7]. Consistently, we have demonstrated that activation of 
immune-related signaling pathways in dysplastic lesions 
and early HCC is important for the sequential evolution 
of liver cancer and precedes the acquisition of malignant 
features in progressed HCC [8]. Therefore, activation 
of molecular changes involved in inflammation as well 
as cancer should be considered in the pursue to identify 
novel therapeutic targets [3]. Importantly, activation 
of inflammation related gene-sets not only impairs the 
development of HCC, but possesses profound prognostic 
implications [9]. A recent study further showed that gene 
expression signatures generated from surrounding non-
tumor liver tissue could accurately predict the patient 
outcome in HCC, whereas signals from the tumor did not 
provide a meaningful clinical association [10].
Several immune response-related and pro-
oncogenic molecules induce opposing effects when 
activated in diverse parenchymal and non-parenchymal 
cell types (e.g. immune cells versus hepatocytes) and 
during different states of the chronic liver disease (e.g. 
inflammation, fibrosis, cirrhosis) which underlines the 
critical importance of the interaction of signals from the 
microenvironment and the tumor cells for tumor initiation 
and progression [11, 12]. Other aspects of the tumor-
microenvironment cross talk are synergistic and amplify 
the malignant potential of the tumors [6]. Therapeutically, 
different cell types might augment the anti-cancer activity 
of sorafenib. Further, several studies clearly showed that 
pro-oncogenic changes in the hepatic microenvironment 
during chronic liver inflammation are orchestrated by 
the interaction of parenchymal cells with diverse types 
of non-parenchymal cells [5, 13]. Therefore, a better 
understanding of the tumor-microenvironment interaction 
might open therapeutic options [14]. In the here presented 
study, we analyzed the genome and transcriptome profiles 
of tumor tissue, the invasive tumor margin and peritumoral 
liver tissue of HCC patients from a Western cohort. Our 
results demonstrate that the hepatic microenvironment is 
critical for malignant progression of HCC. While genetic 
alterations continuously increased from the peritumoral 
tissue to the tumor core, prognostic adverse transcriptomic 
signals and stemness features were activated in the 
invasive tumor margin of the tumor surrounding liver 
tissue. These observations suggest that the chronic 
inflammation creates a pro-oncogenic field effect and 
should be considered a hallmark of liver cancer. 
RESULTS
Characterization of the molecular profiles in 
different tumor regions
The importance of the chronic inflammatory liver 
diseases for HCC initiation and progression has been 
repeatedly demonstrated [5]. To characterize in more 
detail the cross-talk between tumor cells and the diseased 
microenvironment and define key molecular mechanisms 
leading to cancer progression, we macroscopically 
dissected non-neoplastic tumor-surrounding liver tissue 
(SL) from the invasive tumor margin/ border (B) as well 
as the core tumor tissue (T). First, we assessed the global 
transcriptome profiles for each of the regions. As expected, 
the highest number of differentially expressed genes was 
found between T and SL (2630 genes), followed by B vs 
SL (590 genes) (Supplementary Table S3). Transcriptomic 
profiles of T and B showed the highest similarity and only 
100 genes showed significant differences (Figure 1A). 
The identified gene expression signatures significantly 
separated the different regions, thus validating that the 
genes effectively stratify for each region (Figure 1B). 
Not unexpectedly, subsequent pathway analysis using 
GeneGo and IPA showed enrichment of genes related to 
pro-proliferative signaling and DNA damage response 
(CCND1, CD4, ABCC4, APEX1, MAPK9, BMI1, 
MAT1A, MLH1, FADD, FOS, PIK3R1, FOS, RAD51C, 
XRCC3) for the T vs SL as well as B vs SL signatures 
(Supplementary Table S4). Furthermore, both the T vs B 
and B vs SL signature showed activation of functional 
networks related to immune response, inflammation and 
IL-6 signaling (CXCL12, CUL1, CDK5, CD82, PIK3R1, 
SMARCA4, ESR1, IKBKG, SPP1, IL17RA, EGR1, 
IGF1, IGFBP1, IFNAR1), confirming the crucial role of 
chronic inflammation and related molecular pathways 
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Figure 1: Transcriptomic and genomic profiles of the different regions. A. Venn diagram demonstrating the overlap between 
the different gene expression signatures. B. Unsupervised hierarchical cluster analysis of the different regions based on the corresponding 
significant genes (SL vs tumor (2630 genes): upper panel; SL vs border (590 genes): middle panel; border vs tumor (100 genes): lower 
panel) C. Gene set enrichment analysis (GSEA) for each of the regions in comparison to all other regions (rest). Normalized enrichment 
score (NES) reflects degree of overrepresentation for each group at the peak of the entire set. Statistical significance calculated by nominal 
P value of the ES by using an empirical phenotype-based permutation test. D. Graphical representation of the genetic alterations in each 
region determined by DNAcopy. Amplifications are depicted and red and losses are depicted in blue. 
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for hepatocarcinogenesis [7]. Additionally, molecules 
related to adverse and pro-metastatic features were also 
highly activated/repressed in the invasive tumor margin 
(CDH1, ABCG5, APOA1, ID2, LAMC1, CTNNA1, MGMT, 
HNF4A, ALDH8A). Next, gene set enrichment analysis 
(GSEA) was performed to delineate the activated gene 
sets characteristic for each region. GSEA confirmed the 
activation of genes involved in pro-oncogenic signaling 
and proliferation in the T region (Figure 1C; lower 
panel) as well as inflammation in the B region (middle 
panel). Further, enrichment of gene sets commonly 
associated with EMT, metastatic traits as well as survival 
was observed for the B region, indicating a potential 
association to the outcome of HCC patients. Interestingly, 
GSEA revealed an abundance of gene sets associated 
with (cancer-) stemness in SL regions (Figure 1C; upper 
panel). These results indicate that the tumor margin (B) is 
enriched in inflammatory gene sets and shows activation 
of adverse signaling pathways, while tumor tissues mainly 
show activation of proliferative genes. Further, our results 
indicate that the hepatic microenvironment contributes to a 
stemness phenotype observed in many human HCCs.
We next assessed the somatic genetic alterations 
present in the different regions by profiling the 
corresponding tissues using Illumina OmniExpress 
arrays followed by GISTIC 2.0 analyses. Overall, 
progression from SL to T showed a continuous increase 
in genetic alterations (Figure 1D; Supplementary Figure 
S2). As expected, recurrent changes of B and T regions 
involved gains in 1q and 8q as well as copy number 
losses in 8p (Figure 1D) [15]. GISTIC analyses based on 
corresponding SL further identified 15 and 8 significantly 
reoccurring focal amplifications in T and B regions, 
respectively (Supplementary Table S3). Notably, the 
only commonly amplified regions in T and B involved 
7q11.21 while other well characterized driver oncogenes 
such as hTERT (5p15.33) were only observed in tumors. 
Among 30 deletion events in T and 39 in B regions, PTX4 
(16p13.3), KIF20B (10q23.31), SYCP2 (20q13.33) and 
9p21.3 (CDKN2A and CDKN2B, MTAP) were prominent 
in both T and B. These results confirm that alterations of 
the genome play a central role for tumor cell proliferation 
in T and B. Further, transcriptome changes observed in 
SL might be predominantly driven by other mechanisms 
(e.g. epigenetics) and potentially induced by the chronic 
inflammation as well as the tumor-microenvironment 
cross-talk. 
Activation of pro-proliferative gene sets in the 
tumors
Our molecular analyses indicated a predominant 
activation of proliferative signaling in the T region that 
Figure 2: Activation of proliferation in tumor tissues. A. Gene set enrichment analysis (GSEA) of the tumor regions in 
comparison to all other regions (rest) indicate an activation of proliferative gene sets. Normalized enrichment score (NES) reflects degree 
of overrepresentation for each group at the peak of the entire set. Statistical significance calculated by nominal P value of the ES by using 
an empirical phenotype-based permutation test. B. Proliferation of cells determined by Ki67 staining. Dashed bars indicating the separation 
between SL and T regions. Right panel shows the graphical representation as number of positive cells estimated based on 10 randomly 
selected view fields (20x magnification). Statistical evaluation based on Friedman- test for multiple group comparisons followed by Dunns 
posthoc test. (n = 22; P-values: *≤ 0.05; **≤ 0.05; ***≤ 0.001). The data are presented as mean fold differences ± SD.
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might reflect tumor cell proliferation thereby potentially 
supporting tumor expansion. Extension of the GSEA for 
the T region confirmed this finding and demonstrated 
an enrichment of gene sets associated with deregulation 
of cellular genes particularly related to tumor cell 
proliferation in cervical cancer [16] as well as genes 
generally associated with proliferation [17] in this region 
(Figure 2A). Notably, despite the proliferative potential 
of these genes and frequent activation in cancer, no 
association to the outcome of patients could be established 
suggesting that the high proliferation observed in many 
solid tumors might not necessarily confer to prognostic 
traits [17]. To confirm that the activation of proliferation 
genes indeed confers to proliferation in the tumors, 
specimens were stained for Ki67 expression (Figure 
2B). As expected, significantly higher Ki67 levels were 
observed in T and B in comparison to SL. Notably, 
although proliferation of cells in T was generally highest, 
expression levels did not significantly differ to those 
observed in the B regions (Figure 2B). 
Activation of stemness in the peritumoral tissue
Since our molecular analyses indicated an 
activation of stemness in the SL region, we next 
assessed the gene expression levels of specific HCC/
differentiation markers (AFP, GPC3, albumin) as well 
as the selected (cancer-) stemness markers (EpCAM, 
CD133, CK19) and pluripotency genes (NANOG). As 
expected, a strong activation in expression levels of AFP 
and GPC3 as well as a concomitant downregulation of 
albumin levels were observed from SL to T (Figure 3A; 
Supplementary Figure S3). Notably, expression of AFP 
was generally low and undetectable by qRT-PCR in the 
majority of cases. Consistently, levels of the stemness and 
pluripotency markers showed a significant decrease from 
SL to T (Figure 3A; Supplementary Figure S3). Of note, 
expression of well-known progenitor cell marker CK19 
was highest in peritumoral tissue and almost absent in 
tumor tissue [18]. However, two of the investigated tumors 
showed a high positivity leading to a high variability and 
explaining the missing statistical significance between SL 
and T (Figure 3A). Results for AFP, GPC3 and EpCAM 
could further be validated in an independent validation 
cohort of HCC patients as well as cirrhotic livers without 
HCCs (Supplementary Figure S4, Table 1B). Importantly, 
activation of EpCAM did not show significant differences 
in cirrhotic livers in the absence of HCC, confirming 
that induction of EpCAM positive cells in the tumor-
surrounding liver is predominantly seen in the context 
of hepatocarcinogenesis (Supplementary Figure S4). 
Interestingly, similar results could also be revealed during 
sequential evolution of liver cancer (Supplementary 
Figure S5). RNA sequencing in patients with synchronous 
co-existence of pre-neoplastic lesions as well as HCC 
confirmed a continuous decrease in stemness genes from 
SL over dysplastic lesions to progressed HCC. 
To confirm that the diseased hepatic tumor 
microenvironment is the critical determinant of stemness 
activation, we next assessed expression levels of the 
stemness genes in livers containing metastasis from 
different primaries (n = 5). Importantly, we found that 
these markers were not induced in the non-diseased liver 
tissue (i.e. in the absence of chronic liver damage) (Figure 
3B, Supplementary Figure S6). However, consistent 
with an aggressive phenotype of metastases, high levels 
of the markers were detected in metastatic cells (Figure 
3B; Supplementary Figure S6). Together, these results 
corroborate that the hepatic microenvironment plays a 
crucial importance for the acquisition of stemness traits 
in HCC. 
Activation of immune cells in the invasive tumor 
border
To confirm the activation of inflammatory gene sets 
and dissect the corresponding immune cells reflected by 
the molecular changes, we limited our GSEA query to 
gene sets with association to immune-related properties. 
We observed a significant enrichment of gene sets 
related to alternative M2 macrophage activation that 
might exert pro-tumorigenic function (Figure 4A). 
Furthermore, molecular signals resembling non-hypoxic 
macrophages that display impaired anti-tumor response 
were enriched in B regions which might further decrease 
the immune response and promote immune escape of 
HCCs. Consistently, a significant increase of CD68 could 
be demonstrated in B vs T regions (Figure 4B; upper 
panel). Additionally, gene sets associated with activated 
tumor-infiltrating CD8 T cells were enriched in the B 
regions. However, we also recognized activation of genes 
indicative of PD-1 function commonly associated with 
exhaustion anti-tumoral T cell function and properties, 
potentially resulting in impaired immune-surveillance. 
Consistently, we observed a significantly higher number 
of CD3-T cells as well as increased PD-1 expression in 
the SL and B region compared to T (Figure 4B). Together, 
these results highlight the importance of immune-
related mechanisms in the invasive B region for tumor 
progression. 
The invasive tumor border is important for HCC 
patient outcome
Finally, we tested the clinical significance of our 
identified SL, B and T signatures and integrated all three 
signatures with our previously published gene expression 
dataset of 53 human HCC. [19] Subsequent Kaplan-
Meier analysis showed that, despite the high proliferative 
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Figure 3: Activation of stemness markers in peritumoral tissues. A. Activation of stemness marker in the different regions 
was determined by confocal imaging. Representative images for AFP (red) and EpCAM (green) staining (upper panel) and CK19 (lower 
panel) containing all different regions (T = tumor, B = border, SL = surrounding liver) are displayed. Dashed bars indicating the separation 
between SL and T regions. White bar representing 100µm. Graphical representation and statistical evaluation (right graphs) for each marker 
based on h-score and Friedman- test for multiple group comparisons followed by Dunns posthoc test. (n = 15; P-values: *≤ 0.05; **≤ 
0.05; ***≤ 0.001). The data are presented as mean fold differences ± SD. B. Activation of stemness marker EpCAM (green) by confocal 
microscopy. Images contains representation of all different regions (M = metastasis, B = border, SL = surrounding liver). White bar 
representing 200µm. Graphical representation and statistical evaluation (right graphs) for each marker based on h-score and Friedman- test 
for multiple group comparisons followed by Dunns posthoc test. (n = 5; P-values: *≤ 0.05; **≤ 0.05; ***≤ 0.001). The data are presented 
as mean fold differences ± SD.
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Figure 4: Activation of inflammatory gene sets and immune cells in the invasive tumor margin. A. Gene set enrichment 
analysis (GSEA) of the surrounding liver regions in comparison to all other regions (rest) indicate an activation of gene sets involved 
in macrophage as well as T cell activation/function. Normalized enrichment score (NES) reflects degree of overrepresentation for each 
group at the peak of the entire set. Statistical significance calculated by nominal P value of the ES by using an empirical phenotype-
based permutation test. B. Representative H&E stainings are shown in the upper graph. Immunohistochemistry of CD68 and CD3 
demonstrating activated macrophages and T cells. Lower panel shows representative images of PD-1 staining reflecting impaired T cell 
function. Dashed bars indicating the separation between SL and T regions. White arrows indicating selected positive cells. Right panels 
show the corresponding graphical representations as number of positive cells estimated based on 10 randomly selected view fields (20x 
magnification). Statistical evaluation based on Friedman- test for multiple group comparisons followed by Dunns posthoc test. (n = 22; 
P-values: *≤ 0.05; **≤ 0.05; ***≤ 0.001). 
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activity, the T vs SL signature did not possess prognostic 
significance (Figure 5A). However, both the B vs SL and 
B vs T signatures independently classified HCC patients 
according to survival (Figure 5B and 5C). The prognostic 
impact of both signatures could further be confirmed 
in an independent cohort from 247 HCC patients 
(Supplementary Figure S7). Overall, the prognostic 
impact of signatures derived from signals of the B region 
underlines the clinical importance of the invasive tumor-
front that might be helpful to identify novel therapeutic 
targets.
DISCUSSION
The notion that HCC patients display two 
diseases that are inextricably linked to each other, 
i.e. a chronic liver disease and a malignant tumor, is 
increasingly recognized, whereby the diseased hepatic 
microenvironment significantly promotes cancer initiation 
and progression while concomitantly limiting aggressive 
therapeutic approaches [20]. Therefore, the importance of 
the chronic inflammatory liver disease can be considered 
a hallmark feature of HCC and has become focus of 
intense research [3, 21]. We here provide evidence that 
chronic changes of the liver microenvironment induce 
an adverse pro-oncogenic niche that might lead to 
the activation of stemness features and pre-dispose to 
liver cancer development. Heterogeneous patterns of 
molecular alterations present in tumor surrounding liver 
tissue suggest that a potential field cancerization might 
significantly contribute to hepatocarcinogenesis [22]. 
Further, our transcriptome analyses indicate that the 
cross-talk between the inflammatory microenvironment 
and the tumor cells in the invasive tumor border might 
be an important determinant of the patient prognosis 
while tumor cell growth is mainly driven by proliferative 
signaling induced in the tumors.
To address the importance of distinct peritumoral 
and tumoral regions for hepatocarcinogenesis we analyzed 
the molecular profiles of tumor-surrounding liver tissue, 
the invasive tumor border and core tumor tissue by 
genome-wide approaches and at different molecular levels. 
The transcriptome analyses confirmed a distinct gene 
expression profile for each of the different regions (Figure 
1). As expected, most abundant differences were observed 
between T and SL regions and mainly centered around 
functional networks involved in tumor cell proliferation 
as a key feature of tumor expansion [23]. Consistently, 
the tumor region showed the highest amount of cycling 
cells (Figure 2B). Concomitantly, most significant 
genetic alterations were also observed in T regions and 
involved known driver genes of hepatocarcinogenesis 
such as hTERT and CDKN2A and CDKN2B [24, 25]. 
An interesting observation is the activation of stemness 
gene sets and pathways as well as established (cancer-) 
stemness markers in the tumor surrounding liver tissue as 
well as the invasive B region (Figure 3; Supplementary 
Figure S3) [26, 27]. The notion that the acquisition of 
stemness is an important characteristic of malignant 
transformation is well recognized and expansion of 
cells that display progenitor cell features is frequently 
observed in the majority of chronic liver diseases [2, 28, 
29]. A recent study further utilized a monoclonal antibody 
against 1B50-1 to detect a population of cells with CSC 
properties in human HCCs [30]. In concordance with our 
findings, these CSCs were located in the surgical margins 
of primary HCC and possessed prognostic as well as 
therapeutic implications. Our results, therefore, support the 
hypothesis that the permissive hepatic microenvironment 
induces a pro-oncogenic field effect which activates 
stemness traits and ultimately promotes tumor 
development and progression [22, 31, 32]. The relatively 
low number of genetic alterations such as copy-number 
changes further suggests that gene expression changes in 
the SL region are mainly driven by other mechanisms, e.g. 
epigenetic mechanisms, which might support the concept 
of an epigenetic progenitor cell origin in HCC that is 
induced by the chronic inflammatory liver disease [33]. 
Notably, whether the cellular origin of the cells resembles 
hepatocytes or stem progenitor cells remains uncertain 
[7, 34, 35]. Although the decrease in stemness markers 
during sequential hepatocarcinogenesis from SL over 
dysplastic lesions to established HCCs (Supplementary 
Figure S5) favors the hypothesis that these cells contribute 
to tumor development, invasion of stem-like cancer cells 
from the tumor as a reflection of malignant progression 
cannot be excluded [36, 37]. Our analyses also suggest 
that, while the proliferative properties were predominantly 
acquired by tumor cells in the T region, B and SL show 
additional activation of immune-related and pro-metastatic 
signaling. Activation of inflammatory gene sets in tumor-
surrounding liver tissue is a hallmark feature of HCC and 
associated with a poor clinical outcome [10]. Consistently, 
a significantly higher number of both macrophages and 
T cells was seen in SL and B regions compared to T 
regions (Figure 4). Despite several reports that show 
differences in the (immune-)cellular composition in 
the B and SL regions, a recent study also confirmed a 
potential therapeutic impact of this region [38]. Treatment 
with sorafenib induced significant changes to the HCC 
microenvironment by affecting macrophage polarization 
and inhibited accumulation of adverse M2 polarized 
tumor-associated macrophages at the tumor margin or 
within the peritumoral area. We also observed an increased 
number of CD3 T cells in the SL and B region, a feature 
that is commonly associated with an increased tumor-
cell clearance and favorable outcome [39]. However, the 
dominant activation of T cells with enrichment for PD-1 
function suggest that these cells might display impaired 
antitumor activity thereby leading to evasion of tumor-
immuno-surveillance and poor outcome [40-42]. Notably, 
activation of check-point genes such as PD-1/PDL-1 and 
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Figure 5: Prognostic implications of the identified gene expression signatures. Integration of the different gene expression 
signatures with our previously published dataset of 53 HCC patients [19]. Unsupervised cluster analyses (left) and Kaplan-Meier plots of 
overall survival (right) for each of the identified signatures are shown: A. SL vs tumor (2630 genes): upper panel; B. SL vs border (590 
genes): middle panel; C. border vs tumor (100 genes): lower panel).
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CTLA4 could be linked to a poor clinical outcome in 
HCC [40, 41]. Therefore, results of our study owes to the 
promise of immunotherapeutic approaches for liver cancer 
[43]. Importantly, the design of our study does not allow 
the prediction which of the individual patients will show 
a favorable or adverse outcome. Therefore, the activation 
of adverse signaling pathways and putative prognostic 
implications within the B regions are strictly associative. 
Since several reports suggest that infiltrating CD8 T-cells 
in the tumor border might also confer to a favorable 
outcome [39], these observations clearly require a detailed 
functional validation as well as individual confirmative 
analyses. Nevertheless, our results demonstrate a 
therapeutic and prognostic importance of the tumor/liver 
border which is not assessed in the current clinical routine 
(e.g. histology). Our results, therefore, suggest that novel 
diagnostic strategies should include the molecular and 
histological evaluation of the invasive tumor border. In 
line with this, integration of our transcriptome signatures 
with two independent cohorts of HCC patients clearly 
confirmed that the activation of inflammatory and 
adverse signaling pathways in the B regions has a strong 
association with the outcome of HCC patients (Figure 
5; Supplementary Figure S7) [15, 19]. Together, the 
here presented results provide a detailed molecular and 
phenotypic characterization of the different peritumoral, 
border as well tumor regions and highlight the critical 
importance of the diseased hepatic microenvironment for 
HCC initiation and progression. The indicated prognostic 
significance of the cross-talk between tumor cells and 
microenvironment further underlines the recent success of 
immune check-point inhibitors in HCC and makes HCC 
a prime target for immunotherapeutic interventions [43].
MATERIALS AND METHODS
Patient data and nucleic acid extraction
Tissue from 28 patients with confirmed HCC 
undergoing resection at the Department of Surgery, 
University of Mainz, Germany were collected following 
patient informed consent and local ethics committee 
approval. Validation cohort of 20 patients was obtained 
from the Institute of Pathology, University of Basel, 
Switzerland. Clinicopatholigical details are provided in 
Supplementary Table S1. Tissue was macroscopically 
dissected into tumor tissue (T), tumor margin/ border 
(B) (approximately 2-4mm from each region) and peri-
tumoral tissue (SL) (Supplementary Figure S1). Total 
RNA was extracted using the Qiagen RNEasy mini 
Kit (Qiagen GMBH, Hilden, Germany) following the 
manufacturer’s instructions. RNA quantity and purity were 
estimated using a Nanodrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE), and integrity 
was assessed by Agilent 2100 Bioanalyzer (Agilent, Palo 
Alto, CA). DNA was extracted using Qiagen Qiamp DNA 
Kit (Qiagen GMBH, Hilden, Germany) following the 
manufacturer’s instructions. 
Gene expression analysis
A total of 200 ng RNA was linearly amplified as 
recommended by the manufacturer (Ambion, Austin, TX) 
and analyses were performed as described before [44]. 
The microarray datasets have been deposited to Gene 
Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo, accession number: GSE84598). Details of the 
analyses are provided in the Supplementary materials and 
methods.
Immunohistochemistry and confocal microscopy
Diagnosis of HCC was established by expert 
pathologists. Tissue was either fixed in 4% formaldehyde 
and embedded in paraffin or preserved for cryosections 
and cut in 3-5 μm sections. Antibodies and conditions 
for fluorescence and immunohistochemical staining are 
listed in Supplementary Table S2. Fluorescently stained 
tissues were viewed by a Zeiss LSM 710 NLO confocal 
microscope with 25x magnification objective and Tile 
Scan function. Quantification was performed using 
H-score. H-score was determined based on the intensity 
of the staining (0-3) and percent of the positive cells 
(0-100%) in a fixed view field. H-score was calculated 
using the next formula: H-score = 1x(% cells with score 
1)+2x(% cells with score 2)+3x(% cells with score 3). 
Immunohistochemistry was performed by automated 
immunostaining with iVIEW DAB detection kit (Ventana 
Medical System, Roche, Mannheim, Germany) according 
to the company’s protocols. Monoclonal anti-CD68 
(dilution 1:70, DakoCytomation), Ki67 antibodies 
(dilution 1:200, Rockland) and anti-CD3 antibodies 
(dilution 1:100, Santa Cruz) were used. Anti-EpCAM 
antibodies (dilution 1:80, Cell Signaling), anti-GPC3 
antibodies (dilution as given by provider, Ventana 
Medical System, Roche, Basel, Switzerland), anti-AFP 
antibodies (dilution 1:400, DakoCytomation) were 
used. Stained tissues were viewed by a Zeiss Axioskop 
2 plus microscope with 20x magnification objective and 
further analyzed in L.P. Optimas 6.51 software (Media 
Cybernetics). Number of positive cells was estimated in 
ten randomly chosen view fields. All quantifications were 
performed in triplicates.
Statistics, databases and patient integration
Statistical analysis was performed using Student’s 
t-test, Friedman- test for multiple group comparisons 
followed by Dunns posthoc test as indicated. P-values 
≤0.05 were considered statistically significant. Results are 
Oncotarget48698www.impactjournals.com/oncotarget
presented as means ± SD or means ± SEM as indicated. 
Survival analyses were performed using log rank (Mantel-
Cox) tests.
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